JP2019516713A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516713A5
JP2019516713A5 JP2018560569A JP2018560569A JP2019516713A5 JP 2019516713 A5 JP2019516713 A5 JP 2019516713A5 JP 2018560569 A JP2018560569 A JP 2018560569A JP 2018560569 A JP2018560569 A JP 2018560569A JP 2019516713 A5 JP2019516713 A5 JP 2019516713A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
prodrug
acceptable salt
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018560569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516713A (ja
JP7017523B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/033372 external-priority patent/WO2017201313A1/en
Publication of JP2019516713A publication Critical patent/JP2019516713A/ja
Publication of JP2019516713A5 publication Critical patent/JP2019516713A5/ja
Application granted granted Critical
Publication of JP7017523B2 publication Critical patent/JP7017523B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018560569A 2016-05-18 2017-05-18 代謝性疾患および癌の治療のための新規のミトコンドリア脱共役剤 Active JP7017523B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338190P 2016-05-18 2016-05-18
US62/338,190 2016-05-18
PCT/US2017/033372 WO2017201313A1 (en) 2016-05-18 2017-05-18 Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer

Publications (3)

Publication Number Publication Date
JP2019516713A JP2019516713A (ja) 2019-06-20
JP2019516713A5 true JP2019516713A5 (https=) 2020-06-25
JP7017523B2 JP7017523B2 (ja) 2022-02-08

Family

ID=60326610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560569A Active JP7017523B2 (ja) 2016-05-18 2017-05-18 代謝性疾患および癌の治療のための新規のミトコンドリア脱共役剤

Country Status (6)

Country Link
US (1) US10227315B2 (https=)
EP (1) EP3458454B1 (https=)
JP (1) JP7017523B2 (https=)
CN (1) CN109415363B (https=)
CA (1) CA3024610A1 (https=)
WO (1) WO2017201313A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018500388A (ja) 2014-11-18 2018-01-11 ラットガーズ、ザ ステート ユニバーシティ オブ ニュージャージー 代謝疾患及び癌の治療のための、新規ミトコンドリアアンカップラー
CN112040947A (zh) * 2017-12-07 2020-12-04 密歇根大学董事会 Nsd家族抑制剂及用其进行治疗的方法
SI3796975T1 (sl) * 2018-05-22 2024-02-29 Orsobio, Inc. Derivati sulfonilaminobenzamida
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Fxr有限責任公司 含有雙環核心部分之新穎lxr調節劑
WO2020028392A1 (en) 2018-07-30 2020-02-06 Duke University Niclosamide analogues and therapeutic use thereof
CN109503510B (zh) * 2019-01-03 2020-07-03 山东大学 一种防龋抗菌的噻唑类化合物及其制备方法
JP2022521279A (ja) * 2019-02-22 2022-04-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア 男女共用非ホルモン性避妊薬
WO2020231800A1 (en) * 2019-05-10 2020-11-19 Encube Ethicals Private Limited Topical antifungal formulation
WO2021004477A1 (zh) * 2019-07-09 2021-01-14 唐凌峰 一种基于线粒体的药物递送系统及其用途
WO2024054766A2 (en) * 2022-09-08 2024-03-14 Mito Biopharma, Llc Mitochondrial uncouplers for treatment of metabolic diseases and cancer
CN117105809B (zh) * 2023-10-20 2024-05-03 中国农业大学 一种苯甲酰苯胺化合物及其制备方法和应用
CN118206492A (zh) * 2024-03-26 2024-06-18 江南大学 一类2,4-二硝基苯氧基类化合物及其制备方法
WO2026076049A1 (en) * 2024-10-03 2026-04-09 Basf Corporation Fluidized catalytic cracking catalyst with low coke selectivity

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3147300A (en) 1955-09-26 1964-09-01 Bayer Ag Gastropod combating salicylanilides
NL255279A (https=) 1959-08-27
US3909816A (en) 1974-04-29 1975-09-30 Lloyd L Teeters Flame and carbon monoxide sensor and alarm circuit
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4659738A (en) 1985-02-15 1987-04-21 The United States Of America As Represented By The Secretary Of The Army Topical prophylaxis against schistosomal infections
US4983396A (en) 1985-12-06 1991-01-08 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1,3-hexanediol
US4886783A (en) 1986-01-31 1989-12-12 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US4801586A (en) 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US5118845A (en) 1986-09-29 1992-06-02 Whitby Research, Inc. Penetration enhancer for transdermal delivery of systemic agents
US5196410A (en) 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
US4861764A (en) 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
EP1098641B1 (en) 1998-07-27 2016-04-27 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
ATE272633T1 (de) 1998-12-23 2004-08-15 Lilly Co Eli Aromatische amiden
WO2003103648A1 (ja) 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 糖尿病治療薬
JP4743382B2 (ja) 2002-06-06 2011-08-10 株式会社医薬分子設計研究所 O−置換ヒドロキシアリール誘導体
EP1535609A4 (en) 2002-06-10 2009-01-07 Inst Med Molecular Design Inc Nf-kb activation inhibitors
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
ATE468114T1 (de) 2002-11-08 2010-06-15 High Point Pharmaceuticals Llc Sichere chemische entkuppler zur behandlung von fettsucht
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
JP2008545677A (ja) 2005-05-23 2008-12-18 ノボ ノルディスク アクティーゼルスカブ 新規なハロアルコキシ置換サリチル酸アニリド
US7749976B2 (en) 2005-05-24 2010-07-06 The Regents Of The University Of California Isolated PTPMT1 protein which mediates insulin production and uses thereof
AU2007220039A1 (en) 2006-02-27 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of the unfolded protein response and methods for their use
US7659287B2 (en) 2006-06-08 2010-02-09 Amgen Inc. Benzamide derivatives and uses related thereto
CN101842101A (zh) 2007-08-29 2010-09-22 加利福尼亚大学董事会 水杨酰苯胺修饰的肽用作口服治疗剂
WO2009047584A1 (en) 2007-10-11 2009-04-16 Hatchtech Pty. Ltd. Combination compositions and methods of use of the same for controlling infestation
US8211882B2 (en) 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
US20100190832A1 (en) 2008-10-17 2010-07-29 National Institute Of Immunology. Mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and structural templates
WO2012025638A1 (en) 2010-08-27 2012-03-01 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2012040223A2 (en) 2010-09-21 2012-03-29 North Carolina Central University Method for treating non-alcoholic fatty liver disease and type-ii diabetes
US20130231312A1 (en) 2010-11-16 2013-09-05 Shengkan Jin Treatment of type ii diabetes and diabetes-associated diseases with safe chemical mitochondrial uncouplers
KR101434461B1 (ko) 2011-10-21 2014-09-01 한국생명공학연구원 2-하이드록시아릴아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
WO2013164769A1 (en) 2012-05-02 2013-11-07 Lupin Limited Substituted pyridine compounds as crac modulators
JP6238969B2 (ja) 2012-05-08 2017-11-29 エアロミクス・インコーポレイテッドAeromics,Inc. 新規方法
US20130324555A1 (en) 2012-05-29 2013-12-05 Richard Delarey Wood Method of use of pharmaceutical formulations for the treatment of apicomplexan diseases in animals
WO2013192388A1 (en) 2012-06-20 2013-12-27 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
US10351527B2 (en) 2014-04-09 2019-07-16 The University Of British Columbia Binding function 3 (BF3) site compounds as therapeutics and methods for their use
US20170216252A1 (en) 2014-07-11 2017-08-03 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
CN104230787B (zh) 2014-08-20 2016-08-24 华东师范大学 N-(1,3-二氧代异吲哚啉)芳酰胺类化合物及其制备方法和应用
JP2018500388A (ja) * 2014-11-18 2018-01-11 ラットガーズ、ザ ステート ユニバーシティ オブ ニュージャージー 代謝疾患及び癌の治療のための、新規ミトコンドリアアンカップラー

Similar Documents

Publication Publication Date Title
JP2019516713A5 (https=)
JP2019519598A5 (https=)
JP2019518071A5 (https=)
JP2017526677A5 (https=)
JP2019515952A5 (https=)
JP2017511321A5 (https=)
JP2015024998A5 (https=)
JP2017505785A5 (https=)
JP2015508092A5 (https=)
JP2016529324A5 (https=)
JP2007508361A5 (https=)
JP2017515901A5 (https=)
RU2003137561A (ru) 4-замещенные нуклеозиды
JP2013503846A5 (https=)
JP2017531619A5 (https=)
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2008540554A5 (https=)
JP2017503833A5 (https=)
JP2019535723A5 (https=)
JP2015535847A5 (https=)
JP2013519653A5 (https=)
RU2016133471A (ru) Композиции и способы для лечения диабета и заболеваний печени
RU2006135541A (ru) Производные аминокислот
JP2007500222A5 (https=)
JP2013537240A5 (https=)